Delivery Order SPE2DB24D2003-SPE2DB25FXMS5
- Not listed
- The Defense Logistics Agency awarded a $1,061.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector pens. The contract, which is not set-aside and represents a non-competitive delivery order, will be completed by August 5, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $3,347.67 firm fixed price delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector units. The contract, issued on August 22, 2025, with completion targeted for August 25, 2025, represents a non-set-aside, competitively awarded procurement. Performance will be executed from the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $2,520.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 MG/0.5 ML auto-injector supplies (0.5ML). Issued on September 17, 2025, with completion targeted for September 18, 2025, this delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was competitively issued without set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $2,149.65 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on September 5, 2025, with a completion date of September 8, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), an enterprise-wide pharmaceutical prime vendor vehicle valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies, valued at $1,006.78 under a firm fixed-price arrangement. The award, issued on June 30, 2025, with an ultimate completion date of July 1, 2025, represents a non-competitive delivery order. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,268.57 to AmerisourceBergen Drug Corp for XYOSTED 75 MG/0.5 ML auto-injector supplies on August 11, 2025, with completion targeted for August 12, 2025. This firm fixed-price delivery order represents a pediatric/adolescent testosterone replacement therapy product to be performed at the contractor's Conshohocken, Pennsylvania location. The award utilized no set-aside designation, indicating open competitive procurement. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector vials valued at $1,789.66. This is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and represents a non-competitive award under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,678.14 for Xyosted 75 mg/0.5 mL auto-injector supplies on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price, non-set-aside delivery order will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency (DLA) awarded a $1,751.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies on September 2, 2025, with completion targeted for September 3, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle active through December...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, with an ultimate completion date of July 21, 2025. This non-set-aside competitively awarded contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXMS5Delivery Order
The Defense Logistics Agency awarded a $2,172.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector pens on September 15, 2025, with completion scheduled for September 16, 2025. This non-set-aside contract is performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle valued through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies an extensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems. This delivery order for testosterone replacement therapy reflects the company's role in fulfilling specialized pharmaceutical needs across the Defense Health Agency and other government healthcare systems. The transaction is consistent with AmerisourceBergen's demonstrated track record of competitively awarded, non-set-aside contracts with DLA, which encompass brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 9/15/25 |